Omeros Shares Surge as YARTEMLEA Sales Crush Expectations in Q2
First full quarter of YARTEMLEA delivers $28.5M net product sales and turns Omeros profitable on an adjusted basis in Q2 2026.
/ 1648 items
#XY↓
PTC Acquires Near-Approval ST-920 Fabry Gene Therapy in Bankruptcy Auction
PTC Therapeutics acquires BLA-stage ST-920, a one-time AAV gene therapy for Fabry disease, with potential U.S. launch in 2027 and strong clinical data.
Mixed News for Neurocrine: Strong TD Data for INGREZZA, Caution on Vykat XR
Neurocrine reports strong KINECT-PRO results for INGREZZA in tardive dyskinesia quality of life, while experts flag safety risks for Vykat XR.
Cencora Reaffirms Guidance After Limited Walgreens Volume Shift
Cencora reaffirms $17.75–$17.95 FY2026 EPS after minor Walgreens volume shift. Analysts see just 3–3.5% impact as core prime vendor deal stays intact.
Berenberg Downgrades Novo Nordisk to Hold as ‘Battle of the Pills’ Heats Up
Novo Nordisk faces tougher H2. Berenberg downgrades to Hold on rising rivalry with Lilly’s Foundayo.
Definium’s Experimental LSD Drug Delivers Strong Phase 3 Results in Anxiety Trial
Definium’s one-dose anxiety drug cut symptoms for 12 weeks, with mostly mild side effects, offering hope for a new treatment.